{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:10:01Z","timestamp":1776280201234,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003176","name":"Ministerio de Educaci\u00f3n, Cultura y Deporte","doi-asserted-by":"publisher","award":["FPU 14\/03124"],"award-info":[{"award-number":["FPU 14\/03124"]}],"id":[{"id":"10.13039\/501100003176","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13318-020-00625-5","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T09:02:43Z","timestamp":1590051763000},"page":"587-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study"],"prefix":"10.1007","volume":"45","author":[{"given":"Joan","family":"G\u00f3mez-Junyent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Rigo-Bonnin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Benavent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Soldevila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Padull\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Cabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fe","family":"Tubau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"issue":"16","key":"625_CR1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","volume":"351","author":"W Zimmerli","year":"2004","unstructured":"Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645\u201354.","journal-title":"N Engl J Med"},{"issue":"5","key":"625_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11908-008-0064-1","volume":"10","author":"A Trampuz","year":"2008","unstructured":"Trampuz A, Zimmerli W. Diagnosis and treatment of implant-associated septic arthritis and osteomyelitis. Curr Infect Dis Rep. 2008;10(5):394\u2013403.","journal-title":"Curr Infect Dis Rep"},{"issue":"5418","key":"625_CR3","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.284.5418.1318","volume":"284","author":"JW Costerton","year":"1999","unstructured":"Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318\u201322.","journal-title":"Science"},{"issue":"8","key":"625_CR4","doi-asserted-by":"publisher","first-page":"732.e1","DOI":"10.1016\/j.cmi.2016.05.004","volume":"22","author":"N Benito","year":"2016","unstructured":"Benito N, Franco M, Ribera A, Soriano A, Rodriguez-Pardo D, Sorli L, et al. Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect. 2016;22(8):732.e1\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"625_CR5","doi-asserted-by":"publisher","first-page":"254.e1","DOI":"10.1016\/j.cmi.2014.09.007","volume":"21","author":"O Murillo","year":"2015","unstructured":"Murillo O, Grau I, Lora-Tamayo J, Gomez-Junyent J, Ribera A, Tubau F, et al. The changing epidemiology of bacteraemic osteoarticular infections in the early 21st century. Clin Microbiol Infect. 2015;21(3):254.e1\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"625_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1469-0691.2010.03361.x","volume":"17","author":"CA Aboltins","year":"2011","unstructured":"Aboltins CA, Dowsey MM, Buising KL, Peel TN, Daffy JR, Choong PF, et al. Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone. Clin Microbiol Infect. 2011;17(6):862\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"625_CR7","doi-asserted-by":"publisher","first-page":"O911","DOI":"10.1111\/1469-0691.12649","volume":"20","author":"D Rodriguez-Pardo","year":"2014","unstructured":"Rodriguez-Pardo D, Pigrau C, Lora-Tamayo J, Soriano A, del Toro MD, Cobo J, et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect. 2014;20(11):O911\u20139666666666.","journal-title":"Clin Microbiol Infect."},{"issue":"7","key":"625_CR8","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1086\/605593","volume":"49","author":"PH Hsieh","year":"2009","unstructured":"Hsieh PH, Lee MS, Hsu KY, Chang YH, Shih HN, Ueng SW. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis. 2009;49(7):1036\u201343.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"625_CR9","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1093\/jac\/dku151","volume":"69","author":"J Lora-Tamayo","year":"2014","unstructured":"Lora-Tamayo J, Murillo O, Bergen PJ, Nation RL, Poudyal A, Luo X, et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother. 2014;69(9):2434\u201342.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"625_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2958.2008.06152.x","volume":"68","author":"SJ Pamp","year":"2008","unstructured":"Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol. 2008;68(1):223\u201340.","journal-title":"Mol Microbiol"},{"issue":"12","key":"625_CR11","first-page":"3357","volume":"70","author":"A Ribera","year":"2015","unstructured":"Ribera A, Benavent E, Lora-Tamayo J, Tubau F, Pedrero S, Cabo X, et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus beta-lactams. J Antimicrob Chemother. 2015;70(12):3357\u201365.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"625_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/MCC.0b013e3282e2a98f","volume":"13","author":"JW Mouton","year":"2007","unstructured":"Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care. 2007;13(5):598\u2013606.","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"625_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijantimicag.2007.02.002","volume":"30","author":"JA Roberts","year":"2007","unstructured":"Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30(1):11\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"625_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s15010-018-1116-6","volume":"46","author":"A Ribera","year":"2018","unstructured":"Ribera A, Soldevila L, Rigo-Bonnin R, Tubau F, Padulles A, Gomez-Junyent J, et al. Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use. Infection. 2018;46(2):239\u201344.","journal-title":"Infection"},{"issue":"3","key":"625_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/0018578718779009","volume":"54","author":"S Fawaz","year":"2019","unstructured":"Fawaz S, Barton S, Whitney L, Swinden J, Nabhani-Gebara S. Stability of meropenem after reconstitution for administration by prolonged infusion. Hosp Pharm. 2019;54(3):190\u20136.","journal-title":"Hosp Pharm"},{"issue":"3","key":"625_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"625_CR17","doi-asserted-by":"crossref","unstructured":"Anon. Decreased GFR. In: Chapter 1: Definition and classification of CKD. Kidney Int Suppl. 2013;3(1):19\u201362.","DOI":"10.1038\/kisup.2012.64"},{"issue":"4","key":"625_CR18","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204\u2013R212212.","journal-title":"Crit Care"},{"issue":"5","key":"625_CR19","first-page":"565","volume":"64","author":"RL Nation","year":"2017","unstructured":"Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017;64(5):565\u201371.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"625_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","volume":"71","author":"A Ordooei Javan","year":"2015","unstructured":"Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015;71(7):801\u201310.","journal-title":"Eur J Clin Pharmacol"},{"key":"625_CR21","doi-asserted-by":"crossref","unstructured":"Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA. Kucers\u2019 the use of antibiotics. 6th edn. Boca Raton: CRC Press; 2010.","DOI":"10.1201\/b13787"},{"key":"625_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2017.03.009","volume":"468","author":"R Rigo-Bonnin","year":"2017","unstructured":"Rigo-Bonnin R, Ribera A, Arbiol-Roca A, Cobo-Sacristan S, Padulles A, Murillo O, et al. Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of beta-lactam antibiotic concentration in human plasma. Clin Chim Acta. 2017;468:215\u201324.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"625_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1345\/aph.1M717","volume":"44","author":"B Moriyama","year":"2010","unstructured":"Moriyama B, Henning SA, Childs R, Holland SM, Anderson VL, Morris JC, et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother. 2010;44(5):929\u201335.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"625_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1128\/AAC.26.3.388","volume":"26","author":"GL Drusano","year":"1984","unstructured":"Drusano GL, Standiford HC, Fitzpatrick B, Leslie J, Tangtatsawasdi P, Ryan P, et al. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agents Chemother. 1984;26(3):388\u201393.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"625_CR25","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1517\/17425255.2010.506187","volume":"6","author":"Y Hayashi","year":"2010","unstructured":"Hayashi Y, Roberts JA, Paterson DL, Lipman J. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol. 2010;6(8):1017\u201331.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"625_CR26","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1128\/AAC.06349-11","volume":"56","author":"B Miller","year":"2012","unstructured":"Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56(6):3086\u201391.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl B","key":"625_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jac\/32.suppl_B.103","volume":"32","author":"P Van der Auwera","year":"1993","unstructured":"Van der Auwera P, Santella PJ. Pharmacokinetics of cefepime: a review. J Antimicrob Chemother. 1993;32(Suppl B):103\u201315.","journal-title":"J Antimicrob Chemother."},{"key":"625_CR28","doi-asserted-by":"crossref","unstructured":"Vinks AA, van Rossem RN, Mathot RA, Heijerman HG, Mouton JW. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob Agents Chemother. 2007;51(9):3049\u201355.","DOI":"10.1128\/AAC.01522-06"},{"issue":"2","key":"625_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/cid\/cis856","volume":"56","author":"JM Dulhunty","year":"2013","unstructured":"Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2):236\u201344.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"625_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681\u201391.","journal-title":"Am J Respir Crit Care Med."},{"issue":"1","key":"625_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","volume":"18","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"625_CR32","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/jac\/dkw202","volume":"71","author":"O Grossi","year":"2016","unstructured":"Grossi O, Asseray N, Bourigault C, Corvec S, Valette M, Navas D, et al. Gram-negative prosthetic joint infections managed according to a multidisciplinary standardized approach: risk factors for failure and outcome with and without fluoroquinolones. J Antimicrob Chemother. 2016;71(9):2593\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"625_CR33","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1128\/AAC.00126-11","volume":"55","author":"W Hengzhuang","year":"2011","unstructured":"Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. Pharmacokinetics\/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2011;55(9):4469\u201374.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"625_CR34","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1128\/AAC.06486-11","volume":"56","author":"W Hengzhuang","year":"2012","unstructured":"Hengzhuang W, Wu H, Ciofu O, Song Z, Hoiby N. In vivo pharmacokinetics\/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012;56(5):2683\u201390.","journal-title":"Antimicrob Agents Chemother"},{"key":"625_CR35","doi-asserted-by":"crossref","unstructured":"McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T\u2009>\u2009MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31(4):345\u201351.","DOI":"10.1016\/j.ijantimicag.2007.12.009"},{"issue":"5","key":"625_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1128\/AAC.38.5.931","volume":"38","author":"JW Mouton","year":"1994","unstructured":"Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38(5):931\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"625_CR37","first-page":"3178","volume":"70","author":"A Huttner","year":"2015","unstructured":"Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the beta-lactam antibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother. 2015;70(12):3178\u201383.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"625_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1128\/AAC.00389-08","volume":"53","author":"V Zeller","year":"2009","unstructured":"Zeller V, Durand F, Kitzis MD, Lhotellier L, Ziza JM, Mamoudy P, et al. Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations. Antimicrob Agents Chemother. 2009;53(3):883\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"625_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M, Holzgrabe U, Sorgel F. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48(2):89\u2013124.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"625_CR40","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1128\/AAC.00951-13","volume":"57","author":"G Wong","year":"2013","unstructured":"Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, et al. Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57(12):6165\u201370.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"625_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99\u2013110.","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00625-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-020-00625-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-020-00625-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T23:34:33Z","timestamp":1621553673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-020-00625-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s13318-020-00625-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"21 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"J. G.-J. was supported by a grant from the Spanish Ministry of Education (FPU 14\/03124). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare that they did not have any conflict of interest concerning this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval was obtained from the Ethics Committee of Hospital Universitari de Bellvitge (reference EPA045\/16).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}